Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension (Q35076114)

6 August 2017

Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension (English)

1 reference

6 August 2017

1 reference

6

Robyn J Barst

1 reference

6 August 2017

D Dunbar Ivy

1

1 reference

6 August 2017

Aimee K Doran

2

1 reference

6 August 2017

Kelly J Smith

3

1 reference

6 August 2017

George B Mallory

4

1 reference

6 August 2017

Maurice Beghetti

5

1 reference

6 August 2017

Daniela Brady

7

1 reference

6 August 2017

Yuk Law

8

1 reference

6 August 2017

Donna Parker

9

1 reference

6 August 2017

Lori Claussen

10

1 reference

6 August 2017

Steven H Abman

11

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

Journal of the American College of Cardiology

6 August 2017

1 reference

6 August 2017

51

1 reference

6 August 2017

2

1 reference

6 August 2017

161-169

1 reference

Survival in patients with pulmonary arterial hypertension treated with first-line bosentan

6 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Pulmonary arterial hypertension : a comprehensive review of pharmacological treatment

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Sildenafil citrate therapy for pulmonary arterial hypertension

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Response to bosentan in children with pulmonary hypertension

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Treatment of pulmonary arterial hypertension

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Diagnosis and differential assessment of pulmonary arterial hypertension

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Inhaled iloprost for severe pulmonary hypertension

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Inhaled nitric oxide in congenital heart disease.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

CT of the chest in the evaluation of idiopathic pulmonary arterial hypertension in children.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Preliminary experience with bosentan as initial therapy in childhood idiopathic pulmonary arterial hypertension

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Effects of long-term bosentan in children with pulmonary arterial hypertension.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Outcomes in children with idiopathic pulmonary arterial hypertension.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Lower airway obstruction, bronchial hyperresponsiveness, and primary pulmonary hypertension in children

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology

9 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125969

Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study

9 December 2018

1 reference

12 December 2020

Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension

1 reference

12 December 2020

A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension

1 reference

12 December 2020

Bosentan therapy for pulmonary arterial hypertension

1 reference

12 December 2020

Acute hemodynamic effects of pulsed delivery of low flow nasal nitric oxide in children with pulmonary hypertension

1 reference

12 December 2020

Pulmonary flow reserve in children with idiopathic pulmonary arterial hypertension: implications for diagnosis and therapy

1 reference

12 December 2020

Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects

1 reference

12 December 2020

[Pulmonary hypertension associated with congenital heart disease]

1 reference

12 December 2020

10.1016/J.JACC.2007.09.031

Identifiers

DOI

1 reference

6 August 2017

1 reference

6 August 2017

1 reference